GD2 ganglioside peptide mimics (Roswell Park Cancer Institute)

N/A

Report date: 2025/08/22 10:30:50

Base Information

Drug NameGD2 ganglioside peptide mimics (Roswell Park Cancer Institute)
Drug Alias NameJ51 peptide (Roswell Park Cancer Institute)
ClassificationBiologics > Protein drugs > Recombinant polypeptideVaccines > Application > Therapeutic vaccineBiologics > Antigen > Tumor antigen
Mechanisms of ActionDisialoganglioside GD2 modulators
TargetsDisialoganglioside GD2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A